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Abstract
Aims—To verify whether elevated fasting levels of circulating carboxymethyl lysine (CML), an 
advanced glycation end-product (AGE), predict the development of diabetes in middle-age adults.
Methods—Using a stratified case-cohort design, we followed 543 middle-aged individuals who 
developed diabetes and 514 who did not over a median 9 years in the Atherosclerosis Risk in 
Communities Study. Weighted Cox proportional hazards analyses were used to account for the 
design.
Results—In weighted analyses, correlation between CML levels and anthropometric, 
inflammatory or metabolic variables was minimal (Pearson correlations usually <0.10). CML, 
when modelled as a continuous variable and after adjustment for age, sex, race, centre, parental 
history of diabetes, body mass index, waist-to-hip ratio, NEFA, oxidized LDL-cholesterol, 
glomerular filtration rate, smoking, an inflammation score, adiponectin, leptin, insulin, and 
glucose levels, was associated with increased risk of diabetes (HR=1.35; 95% CI 1.09 – 1.67, for 
each 100 ng/mL CML increment). Baseline glucose level and race each modified the association 
(p<0.05 for interaction), which was present only among those with impaired fasting glucose (≥5.6 
mmol/l, HR=1.61, 95%CI 1.26 – 2.05) and among whites (HR=1.50, 95%CI 1.13 – 1.99).
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Conclusions—Elevated fasting CML, after adjustment for multiple risk factors for diabetes, 
predicts the development of incident diabetes, the association being present among those with 
impaired fasting glucose and in whites. These prospective findings suggest that AGE might play a 
role in the development of diabetes.
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Introduction
Advanced glycation end-products (AGE) comprise a heterogeneous group of compounds 
which are formed via a series of non-enzymatic reactions between reducing sugars, proteins 
and lipids [1]. They influence many biological functions, especially as they are irreversibly 
deposited over time in various organs and vessel walls [2]. Serum concentrations of AGE 
have been associated with development of atherosclerosis, microangiopathy, and the severity 
of diabetes complications, including nephropathy and retinopathy [3,4].
Circulating AGE derive not only from endogenous processes, notably in hyperglycaemic and 
hyperlipemic states [5], but also from external sources, the latter mainly from foodstuffs. 
Dry heat, ionization, and irradiation, common industrial processes intended to improve 
safety, digestibility, transportability, and to enhance flavour of foods, generate AGE. Heat 
and dehydration employed in home and commercial cooking, especially in broiling, searing, 
and frying, also significantly increase the content of AGE in foods [5]. In addition, 
circulating AGE may also derive from tobacco as a result of heat drying in its processing and 
combustion during its consumption [6].
Animal studies and small clinical experiments in humans aiming to restrict AGE intake from 
foods, suggest that increased circulating AGE levels may precede, as well as result from, 
diabetes mellitus [5]. However, prospective evidence from cohort studies of free-living 
adults concerning the role of AGE in the development of type 2 diabetes, to our knowledge, 
has not yet been reported. Hence, the aim of the present study is to verify whether elevated 
fasting levels of carboxymethyl lysine (CML), a circulating AGE, predict the development 
of diabetes in free living, middle-age adults.
Patients and Methods
The Atherosclerosis Risk in Communities (ARIC) study recruited a population-based cohort 
of 15,792 individuals aged 45–64 years from four US communities between 1987 and 1989. 
After a baseline clinic examination (visit 1) ARIC conducted three clinic examinations at 
approximately 3-year intervals (visits 2–4), and then a fifth visit in 2011–2013, as well as 
annual telephone interviews. The analyses reported here include information from visits 1–4 
and cover an average of 9 years of follow-up [7]. Human-subject research review 
committees at the involved institutions approved the study, and all participants gave written 
consent. The procedures followed were in accordance with the Helsinki Declaration of 1975, 
as revised in 1983.
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For the present analyses we used a stratified case-cohort design, as previously described in 
the investigation of the role of several inflammation biomarkers in the development of 
diabetes in the ARIC Study [7]. Diabetes was defined based on a self-reported physician 
diagnosis, use of antidiabetic medications, or a fasting glucose value ≥ 7.0 mmol/l at an 
ARIC visit. Prior to sampling, we excluded 2,018 participants with prevalent diabetes, 95 
members of minority ethnic groups with small numbers, 853 individuals who did not return 
to any follow-up visit, 26 with no valid diabetes determination at follow-ups, 7 with 
restrictions on stored plasma use, 12 with missing baseline anthropometric measurements, 
2,537 participants in previous ARIC case-control and case-cohort studies involving 
cardiovascular disease for whom stored plasma was either previously exhausted or held in 
reserve, 45 participants with incomplete fasting (<8 h), and 490 not having values for all 
covariates in previous ARIC studies regarding diabetes aetiology. This left 9740 eligible 
individuals. For 31 individuals new markers were not measured. We selected a race-stratified 
cohort random sample (50% African-American, 50% white), and from the incident cases 
detected between baseline and the 4th ARIC visit we chose a random sample of diabetes 
cases, again stratifying by race (50% African-American, 50% white). This resulted in 1095 
individuals, for whom sampling weights were calculated. We additionally excluded 38 
individuals of the original sample having insufficient remaining plasma to measure AGE. 
Our final sample was thus constructed from 608 participants selected as the cohort random 
sample and 449 participants selected as cases. As 94 of those selected in the cohort random 
sample had developed incident diabetes, our analyses were thus based on a total of 514 non-
cases and 543 cases.
Incident diabetes was determined at ARIC follow-up visits, approximately three years apart. 
The date of onset of diabetes was estimated by interpolation of measured glucose values 
from the visits immediately prior to and during which diabetes was ascertained, as 
previously described [7].
We chose to measure CML as a marker of circulating AGE. Despite the fact that the exact 
chemical structures of most AGE have yet to be determined, several molecular 
configurations have been structurally identified in vivo. CML is among the better 
characterized AGE compounds, and is frequently used to serve as an AGE marker [5].
We analysed CML at a central laboratory in samples collected at the baseline examination 
and stored for approximately 20 years at −70°C. CML concentration was measured in 
duplicate, using an enzyme-linked immunosorbent assay (ELISA) for the quantitative 
determination of CML (MicroCoat., Germany), according to manufacturer’s protocol. This 
assay does not show significant cross-reactivity with other compounds [8]. The CML ELISA 
shows a similar response to both free and protein-bound CML and has been validated [9]. 
Intra- and interassay CV values for CML were 5.5% and 6.5 %, respectively. Although there 
is a paucity of data on the effects of long-term storage on CML measurements in biological 
specimens, our quality control (QC) data shows acceptable CML assay performance and is 
in general agreement with QC data from other studies using the same CML ELISA to 
determine CML concentrations in specimens stored for extended time periods at −70°C 
[10,11].
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Most covariates were measured at baseline by questionnaire, or physical or laboratory 
examination. Low-grade systemic inflammation was estimated, as in previous publications 
from this case-cohort study, by a score ranging from 0 to 6, attributing one point for a value 
greater than the median of the cohort sample for each of six measured inflammation markers 
(IL-6, CRP, orosomucoid, sialic acid, white cell count and fibrinogen) [7].
Glomerular filtration rate (GFR), estimated using the CKD-EPI equation, [12] was added as 
a covariate, as AGE accumulate when renal function is impaired [13].
We used weighted Pearson correlations (and bootstrap confidence intervals) to describe 
crude associations between CML and other variables, and weighted ANCOVA to compute 
adjusted CML means in diabetes cases and non-cases. We performed weighted Cox 
proportional hazards regression to estimate the relation between CML and time to onset of 
diabetes, with weights defined as the inverse of the race-specific sampling fractions, to 
account for the design. In proportional hazards analyses, CML was modelled as a continuous 
variable and as sex-specific quartiles [14]. Adiponectin, body mass index, waist-hip ratio 
and other continuous variables were centred on their means in order to avoid 
multicollinearity.
Linearity of the CML association with diabetes was tested according to the Box-Tidwell 
method [15], considering the Wald test of the variable defined as CML*log(CML), in a 
model that also contained the original CML variable and all other covariates. In addition to 
this, the squared term of the centred CML variable was also tested in a similar model. We 
tested heterogeneity in the CML – incident diabetes association across binary categories of 
covariates using the Wald test of the interaction coefficient. Statistical analyses were 
performed using the SAS (SAS Institute Inc., Cary, NC) and SUDAAN (Research Triangle 
Institute, Raleigh, NC) statistical software packages, reflecting the case-cohort sampling 
design. The proportional hazards assumption was examined through plots of Martingale and 
Schoenfeld residuals [16]. Collinearity across independent variables was investigated with 
linear regression models, variance inflation factors all being < 2.5.
Results
In the weighted cohort random sample, 35.1% of participants were men and 20.2% African-
American, 19.2% were obese (body mass index ≥ 30kg/m2), 21.1% had a parental history of 
diabetes, 19.7% were current smokers, and 31.9% were former smokers. Median (25th 
percentile –75th percentile) age was 52 (48–57) years, and median glomerular filtration rate 
was 68.6 (61.9–76.9) mL/min/1.73m2. Median CML levels were 246.2 (199.5–291.5) 
ng/mL. Other characteristics of cases and cohort representative non-cases have been 
previously reported [7].
Weighted Pearson correlations, assessed in the cohort random sample (n=608), showed no 
statistically significant crude association between CML and anthropometric (body mass 
index and waist/hip ratio), and with most inflammatory (C-reactive protein, IL-6, fibrinogen, 
and orosomucoid), and metabolic (systolic and diastolic blood pressure, adiponectin, leptin, 
triglycerides, HDL-cholesterol insulin, and fasting glucose) variables. An association of 
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small magnitude was found between CML and non-esterified fatty acids (NEFA, r=0.30, 
p<0.001), oxidized LDL-cholesterol (−0.19, p<0.001), and sialic acid (−0.13, p<0.01) (Table 
1).
Mean CML values were higher in men than women [269.6 (95%CI 257.1 – 282.1) vs. 241.3 
(95%CI 233.1 – 249.4) ng/mL, p<0.001], and also higher, though not statistically 
significantly so, in African-Americans than in whites [261.3 (95%CI 249.8 – 272.9) vs. 
248.7 (95%CI 241.1 – 256.2) ng/mL, p = 0.09], after adjustment for possible confounders 
(Table 2).
Individuals who developed diabetes during follow up had greater CML values at baseline 
than those who did not: 263.3ng/mL (95%CI 253.4 – 273.3) vs. 250.1 ng/mL (95%CI 243.9 
– 256.2) after adjustment for age, sex, race and study centre, parental history of diabetes, 
body mass index (BMI), waist-to-hip ratio, NEFA, oxidized LDL-cholesterol, renal function, 
smoking, inflammation score, adiponectin, leptin, insulin and glucose levels at baseline 
(p=0.03).
Survival analyses for incident diabetes modelling CML as a continuous variable as well as 
one categorized in quartiles are presented in Table 3. For every 100 ng/ml increment in 
CML, risk of developing DM increased by 35% [HR = 1.35 (95%CI 1.09 – 1.67)], when 
adjusting for possible confounders (Model 3). No statistically significant association was 
found in less adjusted analyses in which CML was modelled as a continuous variable. When 
CML was modelled categorically, the increased risk [4th vs. 1st quartile HR = 1.44 (95%CI 
0.91 – 2.30)] did not meet nominal statistical significance. Squared CML terms were not 
included in these models, as we were unable to reject linearity of the association between 
diabetes and CML, either by the Box-Tidwell test (p=0.85) or with the simple addition of a 
quadratic CML term (p=0.88).
Investigating heterogeneity in the adjusted continuous variable analysis (Model 3), we found 
no statistically significant effect modification by sex (p=0.14), obesity (p=1.00), current 
smoking (p=0.79), or below/above median glomerular filtration rate (p=0.46). However, the 
association differed by baseline glucose level and race. It was present in those with impaired 
fasting glucose (≥ 5.6 mmol/l; HR=1.61, 95%CI 1.26 – 2.05) but not in those with 
normoglycemia (HR=0.86, 95%CI 0.55 – 1.35; p for interaction = 0.02). Whites had an 
approximately 50% increased risk (HR=1.50, 95%CI 1.13 – 1.99), in contrast with African-
Americans, for whom no association was found (HR=0.92, 95%CI 0.68 – 1.23; p=0.03 for 
the interaction).
Discussion
We observed an increased risk of diabetes associated with circulating levels of CML, such 
that for each 100 ng/ml increment in CML (approximately the CML interquartile range) the 
risk of developing diabetes increased 35%. The association was present and notably stronger 
in individuals already presenting impaired fasting glucose at baseline (HR=1.61) and in 
whites (HR=1.50) than in African-Americans.
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Concern that the current epidemics of diabetes and other chronic diseases are related to 
environmental and societal dynamics that have produced changes in diet and other lifestyle 
behaviours is widely held [17,18]. How such changes lead to diabetes is a matter of much 
current investigation. Within this context, increased production and consumption of foods 
rich in advanced glycation end products, and circulating AGE levels have received growing 
attention [19]. Serum levels of several AGE molecules are elevated in patients with diabetes, 
and their levels predict complications and mortality [20,21]. Additionally, in a population-
based study of U.S. adults aged 65 and older, higher levels of CML predicted incident 
cardiovascular events [22], as in older community dwelling women AGE levels predicted 
cardiovascular disease mortality [23]. However, to our knowledge, the present study is the 
first large, long-term study to demonstrate a prospective association between circulating 
AGE levels and incident diabetes.
Though previous animal studies and small clinical investigations provide a rationale for 
considering AGE as a potentially causative factor, how AGE might cause diabetes is not 
clear. The literature is quite conflicting with respect to the relationship of AGE to insulin 
sensitivity. In a study in which 18 patients with type 2 diabetes were randomly assigned to a 
4 month period of either a healthy diet or an AGE-restricted diet, the latter achieved by 
boiling, poaching, stewing, or steaming food, while avoiding frying, baking, or grilling, 
without changing the quantity or nutrient composition of food [24], a significant decrease in 
plasma insulin and leptin concentrations and a significant increase in adiponectin levels were 
observed with the AGE restriction, compared to the control diet, in patients who had 
diabetes. However, these associations were not significant in the same experiment in 18 
healthy individuals [24], despite the fact that serum CML levels were statistically reduced. 
This results may be expected, as healthy participants started with normal insulin levels and 
they could not be expected to decrease insulin levels below normal by reducing serum AGEs 
[24]. In other randomized, crossover, diet-controlled intervention trial with 62 healthy 
volunteers, HOMA levels were shown to be lower after 1 month of a diet based on mild 
steam cooking, compared to another that was based on high-temperature cooking [25]. In an 
observational study, circulating CML levels were associated with insulin resistance (HOMA-
IR) in 172 healthy American individuals (an increase of 0.049 ± 0.020 in HOMA-IR for 
each increase of 1 U/mL in CML, p=0.019) [26], but not in another, where no association 
was found for CML despite total AGEs were significantly associated with HOMA-IR index, 
in 322 healthy Japanese participants [27].
In fact, it has been suggested that CML may be more appropriately considered a marker of 
oxidation rather than of glycation, which could explain a weaker correlation of CML than 
that of other AGE markers with insulin levels [27]. The low degree of correlation we 
observed between CML levels and circulating non-esterified fatty acids (NEFA) and 
oxidized LDL-cholesterol, corroborates this suggestion. It has been proposed that NEFA and 
CML may share related glycation properties [6], e.g., fatty acids can act as major donors of 
reactive carbonyls and are believed to be more efficient catalysts of the production of AGE, 
as well as other advanced lipoxidation end products (ALE), than glucose [3]. Moreover, the 
inverse correlation found between CML and circulating oxidized LDL-cholesterol levels can 
be possibly explained by the fact that AGE may contribute to the expression of oxidized 
LDL receptors in monocyte–derived macrophages, leading to enhanced oxidized LDL 
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uptake, resulting in foam cell transformation [28]. There was also a small negative crude 
correlation between sialic acid and CML levels, but we did not find any study in literature 
that may explain these results. No other significant crude correlation was found between 
CML levels and clinical variables, including inflammation markers, in the present study. 
However, we did not measure oxidative stress, suggested as a putative mechanism regarding 
AGE-incident diabetes association [29]. In a previous study, CML also presented only small 
negative associations with BMI (−0.15, p<0,001), waist-hip ratio (−0.11, p<0,001) and 
fasting insulin (−0.09, p<0,001) [22]. In this study we first adjusted analyses for basic 
confounders (age, sex and race), and then for major diabetes risk factors (obesity and 
parental history of diabetes), in addition to smoking and renal function (related to AGE 
formation and clearance), NEFA and oxidized LDL cholesterol (correlated to CML levels in 
crude analyses), and finally to other well known [30] mediators in the aetiology of diabetes 
(inflammation score, adipocytokines, and baseline insulin and glucose levels). We presented 
3 separated models since controlling for possible mediators may have a different 
interpretation (looking for a residual association that may occur due to different pathways, 
not mediated by these known mediators). Unfortunately, we cannot clearly differ 
confounding from mediation in our data. For instance, increased AGE level can be a marker 
of higher level of glycaemia, as a confounder, while hyperglycaemia is also an obvious 
mediator to incident diabetes. The fact that the association between CML and incident 
diabetes was still significant after controlling for baseline glucose levels thus suggests that 
other mechanisms may also be involved in this association.
The significant interaction, showing that the association was present only among individuals 
with impaired fasting glucose might indicate that higher AGE levels may only confer risk 
during the later phases of the development of diabetes. One could speculate that the 
combination of external source AGE and AGE produced internally as a result of mild 
hyperglycaemia overwhelm mechanisms to maintain bodily homeostasis with respect to 
these molecules. We have no explanation as to why the association we found was present 
only among white participants.
Our study has several strengths – its relatively large sample of free-living individuals, 
adjustment for multiple potential confounders, and detailed and repeated ascertainment of 
incident diabetes. However, its limitations should be acknowledged. We measured only one 
AGE – CML – and associations with other AGE compounds may be different. We measured 
CML in long term frozen samples, we have no data on sample stability regarding AGE 
levels, it was measured only in a fasting state, and we had no measure of AGE content in 
foods the participants usually consumed. Additionally, the association we found was small, 
being present only in fully adjusted models, and only when CML was expressed in a 
continuous form.
In conclusion, this case-cohort study provides evidence, to suggest that elevated circulating 
AGE levels may increase diabetes risk. Given the supportive findings from animal studies, 
and the potential for major public health importance of an association of diabetes with this 
common, modifiable exposure [5], further investigation of this association is warranted.
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What’s new?
• This is the first large prospective study of free-living adults concerning 
the role of an advanced glycation end-product (AGE) in the 
development of diabetes.
• Our results show increased risk of diabetes associated with circulating 
levels of carboxymethyl lysine.
• These are relevant findings, since circulating AGE derive not only from 
endogenous processes, notably in hyperglycaemic and hyperlipemic 
states, but also from external sources, mainly from foodstuffs, 
configuring a potentially modifiable exposure.
• The association between CML levels and incident diabetes is especially 
present among individuals with impaired fasting glucose and in whites.
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Table 1
Pearson correlations for crude associations of carboxymethyl lysine (CML) levels with inflammation and 
metabolic variables at baseline in the weighted cohort random sample. Atherosclerosis Risk in Communities 
Study.
Pearson correlation coefficient (95%CI)
Age (years) 0.017 (−0,078 – 0,116)
N cigarettes per day * N years of smoking 0.029 (−0,063 – 0,128)
Body mass index −0.058 (−0.147 – 0.029)
Waist −0.062 (−0.160 – 0.039)
Waist-to-hip ratio −0.048 (−0.139 – 0.048)
Creatinine 0.031 (−0,055 – 0,114)
Glomerular filtration rate −0.006 (−0,093 – 0,088)
C-reactive protein −0.062 (−0,153 – 0,040)
IL-6 −0.012 (−0,085 – 0,058)
Fibrinogen −0.041 (−0,127 – 0,044)
Orosomucoid −0.085 (−0,174 – 0,008)
Sialic acid −0.135 (−0,224 – −0,043)*
White blood count 0.042 (−0,046 – 0,123)
Complement component 3 −0.007 (−0,101 – 0,084)
Adiponectin 0.078 (−0,016 – 0,173)
Leptin −0.075 (−0,156 – 0,012)
Non-esterified fatty acids 0.301 (0,214 – 0,386) †
Triglycerides −0.004 (−0,091 – 0,090)
HDL-cholesterol 0.054 (−0,038 – 0,145)
Oxidized LDL-cholesterol −0.190 (−0,290 – −0,087)†
Systolic blood pressure 0.047 (−0,048 – 0,143)
Diastolic blood pressure −0.026 (−0,119 – 0,065)
Fasting insulin 0.003 (−0,066 – 0,072)
HOMA-IR −0.002 (−0,070 – 0,065)
Fasting glucose −0.074 (−0,160 – 0,013)
*p<0.01;
†p<0.001.
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Table 2
Carboxymethyl lysine (CML) levels at baseline in the cohort random sample. Atherosclerosis Risk in 
Communities Study.
n Weighted proportion Mean CML* (95%CI), ng/mL p value†
Sex
 Women 402 64.9% 241.3 (233.1 – 249.4) <0.001
 Men 206 35.1% 269.6 (257.1 – 282.1)
Ethnicity
 African-American 295 20.2% 261.3 (249.8 – 272.9) 0.09
 White 313 79.8% 248.7 (241.1 – 256.2)
Age
 45–54 years 409 64.9% 237.9 (218.1 – 257.7) 0.18
 55–64 years 199 35.1% 247.7 (240.1 – 255.4)
GFR (1st quartile) ‡
 Yes 122 24.7% 254.9 (241.2 – 268.6) 0.54
 No 486 75.3% 250.0 (243.0 – 257.0)
Smoking
 Current 133 19.7% 250.3 (237.8 – 262.8) 0.91
 Former 183 31,9% 253.6 (240.7 – 266.4)
 Never 292 48.4% 250.0 (241.0 – 259.0)
Inflammation score
 High 263 37.3% 253.3 (245.2 – 261.5) 0.41
 Low 345 62.7% 259.1 (239.2 – 279.0)
Body mass index
 Normal 194 39.1% 256.3 (245.6 – 267.0) 0.42
 Overweight 245 41.7% 246.7 (237.6 – 255.8)
 Obese 169 19.2% 250.6 (235.1 – 266.1)
*Adjusted for age, sex, race/centre, parental history of diabetes, BMI, BMI2, waist-to-hip ratio, NEFA, oxidized LDL-cholesterol, glomerular 
filtration rate (CKD-EPI), smoking (cigarettes/day*years), inflammation score, adiponectin, leptin, ln-insulin, and glucose (baseline values)
†Weighted ANCOVA
‡Glomerular filtration rate < 61.8 mL/min per 1.73 m2
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